Abstract:OBJECTIVE:The optimal treatment for primary non-Hodgkin's lymphoma (NHL) of the nasal cavity remains controversial. This study was to analyze the initial response rate of radiotherapy and chemotherapy, and the influence of different treatment modalities on prognosis.METHODS:From January 1996 to December 2002, the clinical data of 129 patients with previously untreated nasal NHL were retrospectively reviewed with all lesions confirmed by pathology. 116 patients were morphologically diagnosed as having nasal NK/T cell lymphoma. The immunophenotype was available in 57 cases and 52 (91.2%) of them were confirmed as NK/T-cell lymphoma. According to the Ann Arbor Staging System, 102 patients had stage I(E), 22 stage II(E), and 5 stage IV(E) disease. Among the 124 patients with stage I(E) and II(E) diseases, 22 patients received radiotherapy alone, 7 chemotherapy alone, and 95 combined modality therapy (CMT). Of these 95 patients treated with CMT, 45 patients were treated with radiotherapy followed by chemotherapy, and 50 with chemotherapy followed by radiotherapy. The primary treatment for stage IV(E) patients was chemotherapy with or without radiotherapy to the primary tumor.RESULTS:The overall 5-year survival (OS) and disease free survival (DFS) for all patients was 68.0% and 55.8%, respectively. It was 71.7% and 60.9% for stage I(E), and 70.6% and 47.0% for stage II(E), respectively (P > 0.05). The OS and DFS at the 5th year were 83.1% and 68.0% for patients who achieved complete response (CR), and 18.0% and 15.5% for those who did not, respectively (P = 0.000). Of the 124 patients with stage I(E) and II(E) disease, 67 patients were treated with radiotherapy alone (22 patients) or radiotherapy followed by chemotherapy (45), whereas 57 were treated with chemotherapy followed by radiotherapy (50) or chemotherapy alone (7). The CR rate after radiotherapy was 74.7%, however, it was only 19.3% after chemotherapy (P = 0.000). Of the 46 patients with PR, SD or PD after chemotherapy, 42 still had locoreginally localized lesion and 31 of these patients achieved CR by following radiotherapy which revealed satisfactory results. For stage I(E) and II(E) disease, the 5-year OS and DFS were 76.0% and 65.0% for radiotherapy with or without chemotherapy, and 74.4% and 56.2% for chemotherapy followed by radiotherapy. The difference was statistically not significant. However, 7 stage I(E) and II(E) patients were treated with chemotherapy alone, and 4 of them died of disease progression, with 1-year survival of 26.7%.CONCLUSION:The majority of Chinese patients with primary nasal NHL are NK/T cell in origin. The complete response rate by radiotherapy is much higher than that by chemotherapy. The addition of chemotherapy to radiotherapy did not improve the survival of patients with early stage nasal lymphoma. Radiotherapy is suggested as the primary treatment for stage I(E) and II(E) nasal NK/T cell lymphoma.

Primary Radiotherapy Showed Favorable Outcome in Treating Extranodal Nasal-Type NK/T-cell Lymphoma in Children and Adolescents

Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma.

Clinical Features and Prognosis of Nasal Type NK/T Cell Lymphoma

Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy.

Unfavorable Prognosis of Elderly Patients with Early-Stage Extranodal Nasal-Type NK/T-cell Lymphoma

[Treatment Option and Outcome for Patients with Primary Non-Hodgkin's Lymphoma of the Nasal Cavity].

Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiation Therapy for Patients with Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.

Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma

Nasopharyngeal/Nasal Type Peripheral T-Cell Lymphomas: Long-Term Outcomes And Prognostic Analysis Of 112 Cases In Southern China.

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma

Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type

The Clinical Features and Prognostic Factors of 104 Cases of Nasal Natural Killer/T-Cell Lymphoma

Role of radiotherapy in the combined treatment of patients with early stage extranodal nasal type NK/T-cell lymphoma and analysis of prognostic factors

The clinical study of extranodal natural killer cell lymphoma, nasal type

Nasopharyngeal Carcinoma in Children and Adolescents in an Endemic Area: A Report of 185 Cases

Clinical Analysis of Radiotherapy for Nasopharyngeal Carcinoma in 145 Children and Adolescents

Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma